Literature DB >> 16286570

A population association study of angiotensinogen polymorphisms and haplotypes with left ventricular phenotypes.

Laura J Rasmussen-Torvik1, Kari E North, C Charles Gu, Cora E Lewis, Jemma B Wilk, Aravinda Chakravarti, Yen-Pei C Chang, Michael B Miller, Na Li, Richard B Devereux, Donna K Arnett.   

Abstract

Several studies have shown an association between single nucleotide polymorphisms (SNPs) in the angiotensinogen (AGT) gene and hypertension. Because hypertension is a risk factor for left ventricular (LV) hypertrophy and because evidence from animal models suggests that AGT may play a role in the growth and hypertrophy of the heart, we chose to conduct a population association study examining the relationship of 10 SNPs in the AGT gene with 7 different LV phenotypes measured by echocardiography. Participants (336 whites and 441 blacks) were drawn from the Hypertension Genetic Epidemiology Network (HyperGEN) study. Individuals were genotyped for 10 previously identified SNPs within the AGT gene. SNP genotype results were regressed against continuous LV phenotypes to test associations separately in each race. Using a cutoff of P<0.005 to account for multiple testing, we found 1 SNP (rs943580) significantly associated with transmitral early peak filling velocity (MVE) in the black population. We also used Phase 2.0.2 to reconstruct haplotypes from genotype data. Using the same cutoff of P<0.005, we found no haplotypes to be significantly associated with the LV phenotypes. To better understand the association between rs943580 and MVE, we examined AGT haplotype associations with MVE. The single SNP association was driven by a large group of SNPs in high linkage disequilibrium that includes the promoter SNP rs5051.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16286570     DOI: 10.1161/01.HYP.0000192653.17209.84

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  7 in total

1.  Transgenic mice with -6A haplotype of the human angiotensinogen gene have increased blood pressure compared with -6G haplotype.

Authors:  Sudhir Jain; Andrej Tillinger; Brahmaraju Mopidevi; Varunkumar G Pandey; Chetankumar K Chauhan; Steven N Fiering; Soren Warming; Ashok Kumar
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

Review 2.  Hereditary determinants of human hypertension: strategies in the setting of genetic complexity.

Authors:  Pei-an Betty Shih; Daniel T O'Connor
Journal:  Hypertension       Date:  2008-04-14       Impact factor: 10.190

3.  Heritability of left ventricular structure and function in Caucasian families.

Authors:  Yu Jin; Tatiana Kuznetsova; Murielle Bochud; Tom Richart; Lutgarde Thijs; Daniele Cusi; Robert Fagard; Jan A Staessen
Journal:  Eur J Echocardiogr       Date:  2011-03-11

4.  A polymorphism in intron I of the human angiotensinogen gene (hAGT) affects binding by HNF3 and hAGT expression and increases blood pressure in mice.

Authors:  Brahmaraju Mopidevi; Meenakshi K Kaw; Indu Sivankutty; Sudhir Jain; Sravan Kumar Perla; Ashok Kumar
Journal:  J Biol Chem       Date:  2019-06-14       Impact factor: 5.157

5.  Human angiotensinogen +11525 C/A polymorphism modulates its gene expression through microRNA binding.

Authors:  Brahmaraju Mopidevi; Madhusudhan Ponnala; Ashok Kumar
Journal:  Physiol Genomics       Date:  2013-08-13       Impact factor: 3.107

6.  Whole-exome sequencing and an iPSC-derived cardiomyocyte model provides a powerful platform for gene discovery in left ventricular hypertrophy.

Authors:  D Zhi; M R Irvin; C C Gu; A J Stoddard; R Lorier; A Matter; D C Rao; V Srinivasasainagendra; H K Tiwari; A Turner; U Broeckel; D K Arnett
Journal:  Front Genet       Date:  2012-05-28       Impact factor: 4.599

Review 7.  Identifying potential functional impact of mutations and polymorphisms: linking heart failure, increased risk of arrhythmias and sudden cardiac death.

Authors:  Benoît Jagu; Flavien Charpentier; Gilles Toumaniantz
Journal:  Front Physiol       Date:  2013-09-20       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.